共 142 条
[1]
McGuire DK(2021)Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis JAMA Cardiol 6 148-158
[2]
Shih WJ(2021)Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Lancet Diabetes Endocrinol 9 653-662
[3]
Cosentino F(2022)Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTs Am J Cardiovasc Drugs 22 69-81
[4]
Sattar N(2019)SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis Lancet Diabetes Endocrinol 7 845-854
[5]
Lee MMY(2020)Dapagliflozin in patients with chronic kidney disease N Engl J Med 383 1436-1446
[6]
Kristensen SL(2019)Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 381 1995-2008
[7]
Qiu M(2019)9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2019 Diabetes Care 42 S90-S102
[8]
Ding LL(2021)Trends in diabetes treatment and control in U.S. adults, 1999-2018 N Engl J Med 384 2219-2228
[9]
Zhou HR(2022)Persistent disparities in diabetes medication receipt by socioeconomic disadvantage in Australia Diabet Med 39 e14898-2332
[10]
Neuen BL(2020)The high cost of diabetes drugs: disparate impact on the most vulnerable patients Diabetes Care 43 2330-818